Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 --
-- New data demonstrating superiority as a heterologous booster compared to inactivated vaccine, robust neutralization of globally dominant Omicron BA.5 strain, and 84% reduction in transmission of SARS-CoV-2 infection to household contacts --
-- Clover poised to become a unique, integrated, vaccine-focused company with established China and global R&D, manufacturing and commercialization capabilities, and an innovative vaccine portfolio --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.